Latest Breaking News On - Qualitative survey - Page 4 : comparemela.com

Share this article TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/   Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new analyses of Dupixent ® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis will be presented at the American Academy of Dermatology Annual Meeting (AAD VMX 2021) from April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021) from May 12-14. Atopic dermatitis is a debilitating disease that spares no age group and is associated with persistent itch and painful lesions that can impair quality of life, affecting the entire family, said Bola Akinlade, M.D., Vice President, Clinical Sciences, Immunology and Inflammation, at Regeneron

United statesSebastien barbarotGil yosipovitchJonathani silverbergGeorged yancopoulosAmys pallerMark hudsonRegeneron velocimmuneStephan weidingerHannah kwaghMark boguniewiczAndrew blauveltAmerican academy of dermatology annual meetingWorldwide survey shows that atopic dermatitis isTeva pharmaceutical industries ltdDupilumab treatment improves health